Indacaterol
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Indacaterol
- Indacaterol: From Chronic Obstructive Pulmonary Disease to Nephrogenic Syndrome of Inappropriate Antidiuresis
Indacaterol: From Chronic Obstructive Pulmonary Disease to Nephrogenic Syndrome of Inappropriate Antidiuresis
One-Sentence Summary
Indacaterol is a long-acting inhaled β2-adrenergic agonist (LABA), publicly known for its established use in chronic obstructive pulmonary disease (COPD) and asthma maintenance therapy. The TxGNN model predicts it may be effective for Nephrogenic Syndrome of Inappropriate Antidiuresis (NSIAD), but this prediction is currently supported by 0 clinical trials and 0 publications — it is a model-score-only signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | COPD (chronic obstructive pulmonary disease) — note: this Evidence Pack contains no Taiwan/EU marketing-authorization or original-indication data; this is based on the drug’s publicly known profile, not pack data |
| Predicted New Indication | Nephrogenic Syndrome of Inappropriate Antidiuresis |
| TxGNN Prediction Score | 99.54% |
| Evidence Level | L5 |
| EU Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for this candidate (flagged as a Blocking/High-severity data gap in the source pack). Based on known information, indacaterol is a long-acting β2-adrenergic receptor agonist, and its efficacy in COPD/asthma bronchodilation is well established; mechanistically, this activity does not have a documented pathway relevant to NSIAD.
NSIAD is caused by a gain-of-function mutation in the vasopressin V2 receptor, leading to inappropriate water retention independent of vasopressin levels. There is no known pharmacological interaction between β2-adrenergic agonism and V2 receptor signaling. The evidence pack’s own rationale is explicit on this point: this pairing has no established mechanistic link, no clinical trials, and no literature support — it reflects the TxGNN model’s statistical prediction score alone.
Given the absence of both mechanistic plausibility and empirical evidence, this specific drug–indication pair should be treated as a low-confidence, exploratory signal rather than a near-term repurposing candidate.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: This candidate is supported only by a TxGNN model score (L5, no clinical or literature evidence), and the proposed mechanism has no known biological basis connecting β2-agonism to the V2-receptor-driven pathology of NSIAD.
To proceed, the following is needed:
- Confirmed mechanism of action (MOA) data for indacaterol (currently a Blocking data gap)
- Preclinical or mechanistic studies exploring any indirect link between β2-adrenergic signaling and vasopressin V2 receptor activity
- TFDA/EMA label warnings and contraindications (currently a Blocking data gap, required before any S1 safety review)
- Ongoing monitoring for emerging clinical trial or case-report evidence
Note: within this same Evidence Pack, a separate predicted indication (“bronchial disease,” rank 7) shows substantially stronger support — L1 evidence level with multiple completed Phase 3 trials and 20 publications — but reflects indacaterol’s already-established core pharmacology (COPD/asthma) rather than a novel repurposing signal. This report follows the pack’s designated top-ranked candidate (NSIAD) per the specified extraction rule.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.